Development

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Gritstone bio, Inc. of Class Action Lawsuit and Upcoming Deadlines – GRTS

Retrieved on: 
Saturday, July 20, 2024

NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Gritstone bio, Inc. (“Gritstone” or the “Company”) (NASDAQ: GRTS) and certain officers.

Key Points: 
  • NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Gritstone bio, Inc. (“Gritstone” or the “Company”) (NASDAQ: GRTS) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Antheia Announces New Funding to Support Domestic Production of Critical Pharmaceutical Ingredients

Retrieved on: 
Friday, July 19, 2024

MENLO PARK, Calif., July 19, 2024 /PRNewswire/ -- Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced $17 million in new funding via a government project agreement through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), alongside matching support from new strategic investors. The combined funding will support onshoring the production of critical pharmaceutical ingredients to the U.S. and accelerating the company's commercialization strategy. The funding includes a non-dilutive two-year project agreement up to $11 million through the BioMaP Consortium and additional investment from In-Q-Tel, Inc. (IQT), Echo Investment Capital (Echo), and several existing investors, including Viking Global Investors.

Key Points: 
  • The combined funding will support onshoring the production of critical pharmaceutical ingredients to the U.S. and accelerating the company's commercialization strategy.
  • "Biotechnology has a critical role to play in U.S. national and economic security," said Dr. Christina Smolke, Antheia CEO and co-founder.
  • As part of the BioMaP-Consortium award, Antheia will demonstrate the domestic production of three critical pharmaceutical ingredients at population scale using advanced biomanufacturing processes.
  • Antheia continues to deliver on its commercial strategy and plans to ship its first orders to customers later this year.

Sify (NASDAQ: SIFY) reports Consolidated Financial Results for Q1 FY 2024-25

Retrieved on: 
Friday, July 19, 2024

The cash balance at the end of the quarter was INR 6,471 Million.”

Key Points: 
  • The cash balance at the end of the quarter was INR 6,471 Million.”
    During the quarter, Sify commissioned 6.5 MW capacity in Mumbai.
  • As of June 30,2024, Sify provides services through 1055 fiber nodes across the country, a 16% increase over same quarter last year.
  • The largest stock exchange, the regulatory body for the securities market, and a national insurance major contracted Sify for a MPLS Network build.
  • Sify was contracted by the highest judicial body in the country for a multi-year Data Center infrastructure build and related managed services.

SIGA Announces U.S. Government Procurement Order of $113 Million for Oral TPOXX®

Retrieved on: 
Friday, July 19, 2024

NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the U.S. Department of Health and Human Services exercised a procurement option for the delivery of approximately $113 million of oral TPOXX® treatment courses.

Key Points: 
  • NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the U.S. Department of Health and Human Services exercised a procurement option for the delivery of approximately $113 million of oral TPOXX® treatment courses.
  • “Building on the orders received in 2023 from the U.S. government and 15 international customers, this $113 million order from the U.S. government will enhance orthopoxvirus preparedness and support sizable and consistent action when needed to help ensure public health from natural, accidental, or intentional threats,” said Diem Nguyen, Chief Executive Officer.
  • “We are pleased to fulfill our responsibility to global health security while generating attractive returns for our company and shareholders.”
    This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) and Strategic National Stockpile, under contract number 75A50118C00019.

Countdown to the first ever Thai innovation and startup network expo 'SITE 2024' at SCI Power For Future Thailand

Retrieved on: 
Friday, July 19, 2024

Additionally, NIA plays a crucial role in policy formulation and facilitating the innovation ecosystem to enhance business potential and value creation.

Key Points: 
  • Additionally, NIA plays a crucial role in policy formulation and facilitating the innovation ecosystem to enhance business potential and value creation.
  • The annual STARTUP THAILAND x INNOVATION THAILAND EXPO (SITE) is a key tool in this endeavor, elevating Thai innovative entrepreneurs and startups by providing them with opportunities for sustainable growth.
  • - Startup Thailand League 2024: National Pitching of Thailand Championship round consists of the final 14 teams of the startup business idea competition activity at the higher education level.
  • For those interested, can get more details and register at https://www.mhesifair.com and Facebook: NIA: National Innovation Agency, Thailand.

PSI and AIB Acquisition Complete Business Combination

Retrieved on: 
Thursday, July 18, 2024

NEW YORK and HONG KONG, July 18, 2024 (GLOBE NEWSWIRE) -- PS International Group Ltd. (together with PSI Group Holdings Ltd and its operating subsidiaries, “PSI” or the “Company”), a long-established global logistics service provider headquartered in Hong Kong specialized in cross-border air freight services, and AIB Acquisition Corporation (Nasdaq: AIB) (“AIB”), a special purpose acquisition company, today announced the completion of their previously announced business combination (the “Business Combination”). PSI’s ordinary shares will commence trading on the Nasdaq under the ticker symbol “PSIG” on July 19, 2024.

Key Points: 
  • - PSI to Debut on Nasdaq on July 19, 2024
    NEW YORK and HONG KONG, July 18, 2024 (GLOBE NEWSWIRE) -- PS International Group Ltd. (together with PSI Group Holdings Ltd and its operating subsidiaries, “PSI” or the “Company”), a long-established global logistics service provider headquartered in Hong Kong specialized in cross-border air freight services, and AIB Acquisition Corporation (Nasdaq: AIB) (“AIB”), a special purpose acquisition company, today announced the completion of their previously announced business combination (the “Business Combination”).
  • Mr. Alex Ko, Chief Executive Officer of PSI, commented: “The listing of PSI on Nasdaq marks a significant milestone in our company’s history, signifying our expansion into the global market.
  • Cooley LLP served as U.S. legal advisor, and Ogier served as Cayman Islands legal advisor to PSI.
  • Ellenoff Grossman & Schole LLP served as U.S. legal advisor, Yin Xu & Co. served as Hong Kong legal advisor, and Collas Crill served as Cayman Islands legal advisor to AIB.

Puttshack Announces Executive Leadership Update, Continues to Drive Operational Excellence and Growth Strategy

Retrieved on: 
Thursday, July 18, 2024

A highly experienced leader, Powell previously served as Global President and Chief Financial Officer of Puttshack since 2019.

Key Points: 
  • A highly experienced leader, Powell previously served as Global President and Chief Financial Officer of Puttshack since 2019.
  • “I have seen firsthand Logan’s exceptional abilities as a leader and his passion for Puttshack,” said Dave Diamond, Puttshack President.
  • Puttshack continues to execute on its long-term growth strategy, bringing its unique concept of tech-led mini golf combined with an upscale food and beverage menu to cities across the country.
  • As part of the company’s growth strategy, Puttshack will continue to innovate on the game technology and guest experience.

3.25 MW Solar Project in Camillus, NY Under Development by SolarBank Secures Permit

Retrieved on: 
Thursday, July 18, 2024

TORONTO, July 18, 2024 /PRNewswire/ - SolarBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) ("SolarBank" or the "Company") announces an update on its 3.25 MW DC ground-mount solar power project located in the Town of Camillus, New York on a closed landfill.

Key Points: 
  • TORONTO, July 18, 2024 /PRNewswire/ - SolarBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) ("SolarBank" or the "Company") announces an update on its 3.25 MW DC ground-mount solar power project located in the Town of Camillus, New York on a closed landfill.
  • (the "Project").
  • The Project is expected to be eligible for incentives under the New York State Energy Research and Development Authority ("NYSERDA") NY-Sun Program.
  • Once completed, the Project will be operated as a community solar project.

Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial Pneumonia

Retrieved on: 
Thursday, July 18, 2024

“With the completion of this post-marketing study, our clinical study database now includes data from 1,438 pneumonia patients and is the largest clinical trial dataset in pneumonia across all antibiotics approved by the FDA in the last decade.

Key Points: 
  • “With the completion of this post-marketing study, our clinical study database now includes data from 1,438 pneumonia patients and is the largest clinical trial dataset in pneumonia across all antibiotics approved by the FDA in the last decade.
  • We believe these data support a near-term opportunity to update the current American Thoracic Society/Infectious Diseases Society of America CAP guidelines.
  • We are extremely grateful to the patients, investigators, Paratek team, and our partners for their commitment to this study.
  • Results of this study will be submitted for publication and for presentation at an upcoming scientific congress.

HAYA Therapeutics Appoints Former Roche Global Head of Operations Eric Adam, Ph.D. as Chief Operating Officer

Retrieved on: 
Thursday, July 18, 2024

HAYA Therapeutics, SA , a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today announced that Eric Adam, Ph.D. has joined as Chief Operating Officer (COO).

Key Points: 
  • HAYA Therapeutics, SA , a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today announced that Eric Adam, Ph.D. has joined as Chief Operating Officer (COO).
  • With over 25 years of experience in health technology and healthcare sectors, Eric joins HAYA’s team in Lausanne after serving as Global Head of Operations within Neuroscience and Rare Diseases in Pharma Research and Early Development (pRED) at Roche.
  • View the full release here: https://www.businesswire.com/news/home/20240712318500/en/
    HAYA Therapeutics, SA, a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today announced that Eric Adam, Ph.D. has joined as Chief Operating Officer (COO).
  • We welcome Eric to the HAYA family,” said Samir Ounzain, Ph.D., Co-founder and CEO of HAYA Therapeutics.